A glycosylated Fc‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide

AIM: To evaluate the pharmacokinetic and pharmacodynamic properties of a novel glycosylated Fc‐fused glucagon‐like peptide‐1(GLP‐1‐gFc) receptor agonist with distinctive receptor binding affinity, designed to improve in vivo stability and safety relative to the commercial GLP‐1 analogue dulaglutide,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: An, In Bok, Byun, Mi Sun, Yang, Sang In, Choi, Yuri, Woo, Jung Won, Jang, Hak Chul, Sung, Young Chul
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7383507/
https://ncbi.nlm.nih.gov/pubmed/32314505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14058
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky